Member Info for Lionel1

Has anyone seen him ? :-)

@popeye , if u sold and made profit then that’s good for you , but why would u take time and post on the BB’s that you are not invested ?? That too rubbish

@Popeye , if u sold out why u hanging here like bad smell ??

*Under delivered

Good bye Popeye, ATB .. you talk lot of nonsense for your 2% . As an investor I am happy about today’s presentation, not over promised and delivered, facts listed .

Some talking nonsense to scare the new so that can beef it out of it , yes papaya I ma talking about you .

@Mystery , You are comparing the Life changing baby test to Russian Roulette ?? I wonder how old are you ?

@amers , I echo your comments about Gecko :-) ,

@Johny , Agree with you , I am expecting slow and organic growth from here , I am happy if it is 10P by Dec 2025 , good for long time investors .

Https://www.linkedin.com/posts/mft-research-and-innovation_congratulations-to-the-paloh-research-team-activity-7268216958351814659-nKKM?utm_source=share&utm_medium=member_ios

“In the last year, the test has been implemented into routine clinical practice at all eight Greater Manchester neonatal units, with funding from Health Innovation Manchester (HInM). So far, the test has prevented the hearing loss of 11 babies at Manchester University NHS Foundation Trust (MFT) and across Greater Manchester, with 4,000 babies tested to October 2024”

https://bivdanewsletter.com/membership-news/bivda-member-genedrive-granted-nihr-ols-funding-for-real-world-evidence/

Thanks James , and they recruiting more ..

https://www.totaljobs.com/job/scientist/genedrive-job103745278?

@Roger , 500k revenue for GDR , They can do whatever they want :-) . I am sure you understood that but u want that lil drama .

Take sysstemzero also if possible , he will take very good guesses :-)

Https://www.itv.com/news/granada/2024-11-21/new-test-to-prevent-newborn-babies-going-deaf-to-be-trialled-across-the-uk

@James @Eureka , Thank you .

OK now I understood , the total cost of the project is 1.4 Mil and 500k directly going to GDR .

I was away and just catching up with the news , so they received 1.4 mil ??

https://mft.nhs.uk/2024/11/21/genetic-test-developed-by-manchester-researchers-to-prevent-newborn-babies-going-deaf-to-be-trialled-across-the-uk/

Now, having successfully received £1.4m funding from the National Institute for Health and Care Research (NIHR) and the Office for Life Sciences, researchers at MFT will lead PALOH-UK, a new two-year study across 14 neonatal units, from large intensive care units to small special care baby units.

Is this misleading ?? Received 1.4 Mil ??

https://www.360dx.com/molecular-diagnostics/uk-provides-ps14m-funding-two-year-study-genedrive-test-prevent-newborn

One more thing to add , Genedrive machine/system is patented but not assays .

For the contrary, I have had a reply couple of months ago , not directly from GDR but from Walbrook . I did send a similar email and had few questions about patents .

“ Genedrive became aware of this a few months ago after this press release was released in the US, but there has been no additional information provided and all that is known is what is in the public domain. It’s worth noting that there are no publications relating to their device or test and their website does not provide any details of stage of progress or regulatory certification.

The genetic test itself isn’t patentable, but first mover advantage is key, as are all of the required regulatory certifications to permit use clinically.

In the UK, NICE have agreed that evidence supports that the Genedrive® MT-RNR1 ID Kit quickly and accurately identifies babies with the MT-RNR1 m.1555A>G variant, who may be at risk of hearing loss if given aminoglycoside antibiotics. Further evidence is being generated in partnership with the Manchester University NHS Foundation Trust and the Royal Sussex County Hospital, Brighton has adopted the Genedrive® MT-RNR1 ID Kit for routine use. The product is also being sold in France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands.

In terms of the US, the Company is at advanced stages in agreeing a partnership with a key strategic USA-based Medical Group with broad coverage of neonatal intensive care units nationally to progress our aim of introduction of our MT-RNR1 point of care pharmacogenetic test to the USA (subject to regulatory approval). Genedrive expect that this partnership would provide a highly cost-effective pathway for the required regulatory studies for potentially attaining approval in the USA.”